Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

2.2K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.2K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

27
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
27
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

478
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
478
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

24
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
24
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

498
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
498
T Cell Types and Functions01:24

T Cell Types and Functions

1.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erosion of Immune Regulation in Diabetic Kidney Disease.

Kidney360·2026
Same author

G-CSF Mediates Increased Renal Neutrophils and Kidney Damage in a Psoriasis Mouse Model.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Impact of Hematopoietic CD14 on Oxidative Stress during Salt-Sensitive Hypertension and Kidney Injury.

Journal of the American Society of Nephrology : JASN·2025
Same author

GWAS for Defining the Pathogenesis of Hypertension: Have They Delivered?

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Endothelial METAP1: Tipping the Angiogenic Scales in Postpartum Preeclampsia.

Circulation research·2025
Same author

Flow Disturbances: Competing Interests in a Case of Hypertensive Emergency.

Hypertension (Dallas, Tex. : 1979)·2024

Related Experiment Video

Updated: Aug 6, 2025

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

5.8K

Modulating T Cell Phenotype and Function to Treat Hypertension.

Daniel J Fehrenbach1, Bianca Nguyen2, Matthew R Alexander1,2,3

  • 1Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.

Kidney360
|March 23, 2023
PubMed
Summary
This summary is machine-generated.

Hypertension damages organs, and current blood pressure control is insufficient. This review explores T cells

More Related Videos

Intracellular Staining and Flow Cytometry to Identify Lymphocyte Subsets within Murine Aorta, Kidney and Lymph Nodes in a Model of Hypertension
09:20

Intracellular Staining and Flow Cytometry to Identify Lymphocyte Subsets within Murine Aorta, Kidney and Lymph Nodes in a Model of Hypertension

Published on: January 28, 2017

18.3K
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
15:33

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

16.0K

Related Experiment Videos

Last Updated: Aug 6, 2025

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

5.8K
Intracellular Staining and Flow Cytometry to Identify Lymphocyte Subsets within Murine Aorta, Kidney and Lymph Nodes in a Model of Hypertension
09:20

Intracellular Staining and Flow Cytometry to Identify Lymphocyte Subsets within Murine Aorta, Kidney and Lymph Nodes in a Model of Hypertension

Published on: January 28, 2017

18.3K
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
15:33

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

16.0K

Area of Science:

  • Immunology
  • Cardiovascular Science
  • Nephrology

Background:

  • Hypertension is a major global health issue, causing significant cardiovascular and renal damage.
  • Existing treatments for hypertension do not fully mitigate end-organ damage.
  • Immune system activation is linked to hypertension, yet targeted immunotherapies are lacking.

Approach:

  • This review examines the role of T cells in hypertension and associated end-organ damage.
  • It identifies potential therapeutic targets within T cell pathways.
  • The focus is on modulating T cell function without causing widespread immunosuppression.

Key Points:

  • T cells play a critical role in hypertension-related cardiovascular and renal damage.
  • Specific T cell subsets and their functions are implicated in hypertensive pathology.
  • Targeting T cell responses offers a novel therapeutic strategy for hypertension.

Conclusions:

  • Modulating T cell phenotype and function presents a promising avenue for novel hypertension therapies.
  • Targeted immunomodulation could improve outcomes in hypertensive patients by protecting end organs.
  • Further research into T cell-specific targets is warranted to develop effective treatments.